Artículo
Low-doses aspirin in the primary prevention of cardiovascular disease in patients with diabetes: Meta-analysis stratified by baseline cardiovascular risk
Masson, Walter; Barbagelata, Leandro; Lavalle Cobo, Augusto; Lobo, Martín; Masson, Gerardo; Nogueira, Juan Patricio
; Vergès, Bruno
![Icon](/themes/CONICETDigital/images/conicet.png)
Fecha de publicación:
01/2022
Editorial:
Elsevier
Revista:
Diabetes and Metabolic Syndrome: Clinical Research and Reviews
ISSN:
1871-4021
e-ISSN:
1878-0334
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Background and aim: The aim of this meta-analysis was to analyze the risks and benefits of low-dose aspirin in patients with T2D without cardiovascular conditions according to the baseline cardiovascular risk. Methods: We performed a meta-analysis including randomized clinical trials that evaluated the use of low-dose aspirin (75–100 mg/day) versus placebo/usual care in patients with T2D. Studies were classified as low, moderate and high risk based on the number of events in the placebo/control arms or by cardiovascular risk score when reported. The incidence of MACE, cardiovascular mortality and bleeding were evaluated. Results: Ten eligible trials (34069 patients) were considered eligible for the analyses. According to the stratified analysis, low-dose aspirin use was associated with reduced risk for MACE in the moderate/high-risk group (OR: 0.88; 95% CI, 0.80–0.97; I2 = 0%) but not in the low-risk group (OR: 0.89; 95% CI, 0.77–1.01; I2 = 0%). Likewise, low-dose aspirin use was associated with more bleeding in the low-risk group, showing a non-significant trend in the moderate/high-risk group. There was no reduction in cardiovascular mortality in either group. Beyond the different findings in each stratum, the differences between the subgroups were not statistically significant. Conclusion: This study showed that low-dose aspirin in patients with T2D reduces MACE and increases bleeding. Based on the within-subgroups results, the baseline cardiovascular risk does not modify the effect of aspirin therapy. However, few studies were included and the comparison between subgroups showed a trend in favor to the highest risk group, these results should be confirmed in future studies.
Palabras clave:
ASPIRIN
,
CARDIOVASCULAR RISK
,
MAJOR CARDIOVASCULAR EVENTS
,
TYPE 2 DIABETES
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(CCT - NORDESTE)
Articulos de CTRO.CIENTIFICO TECNOL.CONICET - NORDESTE
Articulos de CTRO.CIENTIFICO TECNOL.CONICET - NORDESTE
Citación
Masson, Walter; Barbagelata, Leandro; Lavalle Cobo, Augusto; Lobo, Martín; Masson, Gerardo; et al.; Low-doses aspirin in the primary prevention of cardiovascular disease in patients with diabetes: Meta-analysis stratified by baseline cardiovascular risk; Elsevier; Diabetes and Metabolic Syndrome: Clinical Research and Reviews; 16; 1; 1-2022; 1-7
Compartir
Altmétricas